Generics
Amneal Names George, Kiely and Yanai to Board of Directors
18 December 2019 - - US-based pharmaceutical company Amneal Pharmaceuticals, Inc. (NYSE: AMRX) has appointed Jeff George, John Kiely and Shlomo Yanai to the company's board of directors, the company said.

These three new independent directors bring to Amneal extensive records of overseeing growth and creating value in the pharmaceutical and healthcare industries.

Select leadership and industry experience for Amneal's three new directors includes:

Jeff George has nearly 20 years of global healthcare and corporate leadership experience across North America, Europe and emerging markets.

He currently serves as Managing Partner of Maytal Capital, a private equity investment and advisory firm he founded, as well as an operating partner at Revival Healthcare Capital, a medical-device private equity firm.

Among other leadership roles, George previously served as Division Head and CEO of Sandoz, Novartis' USD 10bn generic pharmaceuticals and biosimilars subsidiary, from 2008 to 2014; as Division Head and CEO of Alcon, Novartis' then USD 10bn branded eye care business, from 2014 to 2016; and more recently as CEO and board member of Performance Health, the largest global manufacturer and distributor of products to the physical therapy and rehabilitation markets.

He currently serves on the board of Silicon Valley-based healthcare software firm Roam Analytics and previously served on the boards of AdvaMed (the Advanced Medical Technology Association) and Performance Health Holdings.

John Kiely has more than 35 years of financial leadership and advisory experience serving public companies, including multi-national corporations.

Until June 2019 he served as Senior Assurance Partner at Pricewaterhouse Coopers, where he focused on the pharmaceutical, manufacturing chemical and medical device sectors.

Since 1980, he has held various roles of increasing responsibility at Pricewaterhouse Coopers, including as US Pharmaceutical Leader and Global Pharmaceutical Assurance Leader.

Kiely currently serves on the board at Zovio, Inc.

Shlomo Yanai has more than 15 years of corporate leadership experience, primarily in the pharmaceutical industry.

He most recently served as president and CEO at Teva Pharmaceutical Industries Ltd., from 2007 to 2012, where he increased revenues from USD 8.4bn in 2006 to USD 18.3bn in 2011, and net profit from USD1.9 bn to USD4.4 bn over the same time period.

Yanai also serves as an advisor to CVC Capital Partners, a private equity firm with USD80.5 bn in assets under management.

In addition, he currently serves on the boards of PDL BioPharma Inc. and WR Grace and Co. Yanai previously served on the boards of Cambrex Corp., Lumenis Ltd., Perrigo company and Sageant Pharmaceuticals, among others, and held various leadership positions in the Israel Defense Forces.

Amneal also said that Jean Selden Greene has retired from the Amneal Board, effective as of December 14, 2019. Greene's resignation was not based on any disagreement with the company on any matter relating to the company's operations, policies or practices.

As a result of the foregoing changes on Board composition, the board will comprise eleven directors.

Amneal Pharmaceuticals, Inc. (NYSE: AMRX), headquartered in Bridgewater, NJ, is a fully-integrated pharmaceutical company focused on the development, manufacture and distribution of generic and specialty drug products.

The company has manufacturing operations in North America, Asia, and Europe, working together to bring high-quality medicines to patients primarily within the United States.

Amneal has an extensive portfolio of more than 225 marketed commercial products and is expanding its portfolio to include complex dosage forms, including biosimilars, in a range of therapeutic areas.

The company also markets a portfolio of branded pharmaceutical products through its Specialty segment focused principally on central nervous system and endocrine disorders.
Login
Username:

Password:


Related Headlines